MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice.

ABSTRACT: Congestive heart failure affects about 23 million people worldwide, and cardiac allograft transplantation remains one of the last options for patients with terminal refractory heart failure. Besides the infectious or oncological complications, the prognosis of patients after heart transplantation is affected by acute cellular or antibody-mediated rejection and allograft vasculopathy development. Current monitoring of both conditions requires the performance of invasive procedures (endomyocardial biopsy sampling and coronary angiography or optical coherence tomography, respectively) that are costly, time-demanding, and non-comfortable for the patient. Within this narrative review, we focus on the potential pathophysiological and clinical roles of microRNAs (miRNAs, miRs) in the field of car

SUBMITTER: Novak J 

PROVIDER: S-EPMC8058726 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature